Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

ASTX727

Drug and asset intelligence for ASTX727 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Recent signals(1)

ClinicalJune 30, 2026

Phase I Trial of ASTX727 with Paclitaxel and Pembrolizumab in Metastatic TNBC

A phase I trial is underway to evaluate the safety and efficacy of ASTX727 in combination with standard treatments for metastatic triple-negative breast cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Merck — ASTX727

Monitor trial results for safety and efficacy outcomes, as well as any announcements regarding further development plans for ASTX727.

June 30, 2026 · N/A

Indications

Triple-Negative Breast Cancer →

Therapeutic areas

Oncology · Triple-Negative Breast Cancer →

Triple-Negative Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.